David A. Ramsay
Independent DirectorMr. David A. Ramsay, MBA, is Independent Director of Tang Capital Acquisition Corp. from August 14, 2026. Mr. Ramsay was Interim Chief Financial Officer of Halozyme Therapeutics, Inc. from March 23, 2026 to June 8, 2026 and also serves as President of Drug Delivery Since June 30, 2026. He co-founded Bonti, Inc. and was its CFO from February 2018. Mr. Ramsay has been a Director of EXUMA Biotech Corp. since January 2017. He served as an Independent Director of La Jolla Pharmaceutical Company since October 8, 2019 until August 22, 2022. Mr. Ramsay has Co-founded Bonti, Inc. and had been its Senior Vice President and Chief Financial Officer since February 2018 until its acquisition by Allergan plc in October 2018. Mr. Ramsay provides consulting services to biotechnology companies, both publicly traded and privately-held. He has over many years of corporate financial experience spanning several industries. Mr. Ramsay served as an Executive Advisor of Ignyta, Inc. (alternate name, NexDx, Inc.) since January 2012. From 2003 to 2015, he held various positions at Halozyme Therapeutics, Inc. He served as the Chief Financial Officer of Halozyme Therapeutics, Inc. from May 23, 2013 to June 15, 2015 and previously from March 11, 2003 to May 15, 2009 and served as its Vice President from 2009 to June 15, 2015. He served as Vice President of Corporate Development of Halozyme Therapeutics, Inc. since May 15, 2009 until May 2013 and served as its Secretary. He served as Chief Financial Officer and Vice President at Global Yacht Services, Inc. since March 24, 2004. Mr. Ramsay joined Halozyme in 2003. He served as Vice President and Chief Financial Officer of Lathian Health, Inc. (also known as Lathian Systems) from 2000 to 2003. Mr. Ramsay joined Valeant Pharmaceuticals International, Inc. (Formerly known as ICN) in 1998 from ARCO, where he served for few years in various financial roles. He served as Vice President and Controller of Security Pacific Asian Bank. From 1998 to 2000, he served with Valeant Pharmaceuticals International, Inc. (formerly, ICN Pharmaceuticals, Inc.), where he served as Vice President, Treasurer and Director of Corporate Finance. He served as a Manager of Financial Planning & Analysis for ICN’s 1,700-station West Coast Retail Marketing Network. He began his career as a Senior Auditor (CPA) at Deloitte & Touche, where he obtained his CPA license. He has been an Independent Director at Savara Inc. since April 2017. He serves as a Director of Axxora Life Sciences, Inc. He served as a Director of Bonti, Inc. from 2015 to February 2018. He served as a Director of Mast Therapeutics, Inc. since June 15, 2011 until April, 2017. Mr. Ramsay earned his BS in Business Administration from the University of California, Berkeley and an MBA Degree with a dual major in Finance and Strategic Management from The Wharton School at the University of Pennsylvania and is a Certified Public Accountant (inactive) in the state of California.
Positions
- Company NameSavara Inc.Stock CodeSVRAPositionIndependent DirectorColleagues
- MPMatthew PaulsChairman & CEO
- RMRobert Matthew LutzCOO & CFO
- YWYasmine WasfiChief Medical Officer
- KMKate McCabeChief Legal Officer
- MCMegan CarpenterChief People Officer
- NCNevan Charles ElamIndependent Director
- JSJoseph S. McCrackenLead Independent Director
- DADavid A. RamsayIndependent Director
- RJRichard J. HawkinsIndependent Director
- Company NameHalozyme Therapeutics, Inc.Stock CodeHALOPositionPresident of Drug DeliveryColleagues
- HIHelen I. TorleyPresident, CEO & Director
- JWJeffrey W. HendersonIndependent Chair of the Board
- MSMark SnyderExecutive VP, General Counsel, Chief Compliance Officer & Corporate Secretary
- DSDarren SnellgroveSenior VP & CFO
- BSBrian SweeneyChief Human Resources Officer
- GIGregory I. FrostChairman of Scientific Advisory Board
- MLMatthew L. PosardIndependent Director
- BMBernadette Mary ConnaughtonIndependent Director
